1. Home
  2. RGP vs HUMAW Comparison

RGP vs HUMAW Comparison

Compare RGP & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Resources Connection Inc.

RGP

Resources Connection Inc.

HOLD

Current Price

$4.64

Market Cap

168.6M

ML Signal

HOLD

Logo Humacyte Inc. Warrant

HUMAW

Humacyte Inc. Warrant

HOLD

Current Price

$0.14

Market Cap

0.0

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGP
HUMAW
Founded
1996
2004
Country
United States
United States
Employees
N/A
220
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
168.6M
N/A
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
RGP
HUMAW
Price
$4.64
$0.14
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$6.00
N/A
AVG Volume (30 Days)
395.2K
14.2K
Earning Date
01-07-2026
03-21-2025
Dividend Yield
6.07%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$506,739,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.97
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.13
$1.18
52 Week High
$8.78
$1.34

Technical Indicators

Market Signals
Indicator
RGP
HUMAW
Relative Strength Index (RSI) 39.63 55.89
Support Level $4.24 $0.10
Resistance Level $4.88 $0.15
Average True Range (ATR) 0.21 0.03
MACD -0.07 0.01
Stochastic Oscillator 36.79 96.15

Price Performance

Historical Comparison
RGP
HUMAW

About RGP Resources Connection Inc.

Resources Connection Inc provides consulting and business initiative support services predominantly through its operative subsidiary, Resources Global Professionals. It has two segments RGP ( Resources Global Professionals.) and Sitrick. The RGP segment is focused on delivering consulting services catering to its client's operational needs and change initiatives utilizing a combination of bench and on-demand, talent. The Sitrick segment provides corporate, financial, transactional, and crisis communication and management services. The company generates a majority of its revenue from the RGP segment. Geographically, it derives its key revenue from North America and the rest from Europe and the Asia Pacific region.

About HUMAW Humacyte Inc. Warrant

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Share on Social Networks: